Week of September 7th 2021 | Vol. 10, Issue 38
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products

Project Alamo
Sell-side | CMO | Corporate Carve out - private label and OTC manufacturing business

Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics

Project Aspen
Sell-side | CDMO | Multinational CDMO headquartered in US

Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse
Tia, a startup building what it calls a "modern medical home for women," secured a hefty $100 million funding round to scale its virtual and in-person care.

The company says it marks one of the largest series B investments ever for a healthcare company focused on women, signaling Tia’s anti-fragmentation approach helps shift women’s health from “niche” to mass market. The company, founded in 2017, has raised $132 million to date.

Tia aims to serve 100,000 women by 2023. The company also will use the fresh capital to build out more in-person clinics in existing and new markets while expanding its service lines to care for women throughout their entire lives, from puberty to menopause. Tia also plans to announce new markets next year, Carolyn Witte, co-founder and CEO of Tia, told Fierce Healthcare.
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
11 transactions totaling $1,599 million
Supplies, Equipment & Services
16 transactions totaling $1,237 million
Healthcare IT & Managed Care
3 transactions
Healthcare Facilities & Distributors
14 transactions totaling $1,745 million
Pharma & Biotech
37 transactions totaling $1,455 million
Supplies, Equipment & Services
14 transactions totaling $400 million
Healthcare IT & Managed Care
21 transactions totaling $228 million
Healthcare Facilities & Distributors
1 transaction totaling $1 million
Pharma & Biotech
15 transactions totaling $1,200 million
Supplies, Equipment & Services
4 transactions totaling $1,457 million
Healthcare IT & Managed Care
1 transaction totaling $2 million
Healthcare Facilities & Distributors
0 transactions
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
September 14, 2021 - Fierce Healthcare
Google and ProMedica Health System are jumping into the rapidly growing virtual care market to get a piece of the $213 billion that's spent annually on musculoskeletal care. The two companies are partnering with IncludeHealth to launch a musculoskeletal (MSK) operating system that any provider can use to offer integrated virtual physical care for MSK patients. The platform is hardware-free and device-agnostic, according to the companies. “The landscape of care delivery has shifted,” said John Pigott, M.D., chief innovation officer at ProMedica in a statement.

September 15, 2021 - Fierce Healthcare
Riding the wave of investor interest in the red-hot health tech market, Definitive Healthcare saw its stock surge 50% on its first day of trading Wednesday after raising $420 million in its initial public offering. The healthcare commercial intelligence company went public Wednesday on the Nasdaq exchange offering 15.6 million shares priced at $27 a share. The Framingham, Massachusetts-based company had previously filed to offer the same number of shares at a range of $21 to $24. The stock is listed on the Nasdaq exchange under the ticker symbol "DH." 

September 16, 2021 - Fierce Biotech
In 2017, Joël de Beer dropped out of his Ph.D. program and began trying to build a leading genetic medicines company from a site the size of a parking space. After working quietly for several years to realize the vision, de Beer’s Anjarium Biosciences has now broken cover with 55.5 million Swiss francs ($61 million) from top-tier investors including Abingworth, Gimv and Pfizer Ventures. Anjarium secured the series A funding by persuading investors it could be the company that cracks the challenge of delivering nucleic acid payloads.

September 16, 2021 - Fierce Healthcare
A collection of venture capital funds that invest in pharma and biotech startups issued a dire warning that funding for new drugs will dry up if Democrats move forward with giving Medicare the power to negotiate drug prices for certain drugs and extend those prices to commercial plans. “Investments won’t just be reduced, it will drop off a cliff,” said John Stanford, executive director of venture capital coalition Incubate, during the briefing Wednesday in Washington, D.C. The briefing is the latest escalating rhetoric from the pharmaceutical industry as Democrats aim to include broad Medicare drug price negotiation powers in a $3.5 trillion infrastructure package expected to be voted on this fall. 
Events Hosted or Attended by Bourne Partners

Dates TBD - Charlotte, NC

September 14, 2021 - Virtual Webinar

November 9-11, 2021 - Milan, Italy

January 10-14, 2022 - San Francisco, CA
Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.